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Tissue-specific pathways and networks
underlying sexual dimorphism in non-
alcoholic fatty liver disease
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Frode Norheim2, Zhiqiang Zhou2, Yehudit Hasin2, Aldons J Lusis2* and Xia Yang1*
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) encompasses benign steatosis and more severe conditions
such as non-alcoholic steatohepatitis (NASH), cirrhosis, and liver cancer. This chronic liver disease has a poorly
understood etiology and demonstrates sexual dimorphisms. We aim to examine the molecular mechanisms
underlying sexual dimorphisms in NAFLD pathogenesis through a comprehensive multi-omics study. We integrated
genomics (DNA variations), transcriptomics of liver and adipose tissue, and phenotypic data of NAFLD derived from
female mice of ~ 100 strains included in the hybrid mouse diversity panel (HMDP) and compared the NAFLD
molecular pathways and gene networks between sexes.
Results: We identified both shared and sex-specific biological processes for NAFLD. Adaptive immunity, branched
chain amino acid metabolism, oxidative phosphorylation, and cell cycle/apoptosis were shared between sexes.
Among the sex-specific pathways were vitamins and cofactors metabolism and ion channel transport for females,
and phospholipid, lysophospholipid, and phosphatidylinositol metabolism and insulin signaling for males.
Additionally, numerous lipid and insulin-related pathways and inflammatory processes in the adipose and liver
tissue appeared to show more prominent association with NAFLD in male HMDP. Using data-driven network
modeling, we identified plausible sex-specific and tissue-specific regulatory genes as well as those that are shared
between sexes. These key regulators orchestrate the NAFLD pathways in a sex- and tissue-specific manner.
Gonadectomy experiments support that sex hormones may partially underlie the sexually dimorphic genes and
pathways involved in NAFLD.
Conclusions: Our multi-omics integrative study reveals sex- and tissue-specific genes, processes, and networks
underlying sexual dimorphism in NAFLD and may facilitate sex-specific precision medicine.
Keywords: Non-alcoholic fatty liver disease (NAFLD), Sexual dimorphism, Multi-omics integration, Key regulator
genes, Bayesian networks, Coexpression networks, Hybrid mouse diversity panel
Background
Nonalcoholic fatty liver disease (NAFLD) covers a wide
spectrum of disorders spanning simple liver steatosis, non-
alcoholic steatohepatitis (NASH), cirrhosis, and hepatocel-
lular carcinoma [1–3]. NAFLD has rapidly become a
significant health threat globally, affecting 25% of the world
population on average, and is strongly associated with
insulin resistance, type II diabetes, and obesity [1, 4–6].
Due to the lack of mechanistic understanding of NAFLD,
there are no existing therapies directly targeting NAFLD.
Moreover, significant unexplained age-dependent sexual di-
morphisms have been observed in NAFLD. At younger
ages, NAFLD has a higher prevalence in males than fe-
males, whereas at older ages, especially after menopause,
the prevalence in females increases [7–10]. Males with
NAFLD have more severe metabolic phenotypes than fe-
males, including higher glucose levels, higher systolic blood
pressure, greater visceral adiposity, lower adiponectin levels,
* Correspondence: jlusis@mednet.ucla.edu; xyang123@ucla.edu
2Department of Medicine/Division of Cardiology, David Geffen School of
Medicine, University of California, Los Angeles, Los Angeles, CA, USA
1Department of Integrative Biology and Physiology, University of California,
Los Angeles, Los Angeles, CA, USA
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kurt et al. Biology of Sex Differences            (2018) 9:46 
https://doi.org/10.1186/s13293-018-0205-7
lower high-density lipoprotein cholesterol levels, and
greater liver injury as measured by alanine aminotransfer-
ase levels and aspartate aminotransferase levels [11]. Al-
though endogenous estrogens, adipose distribution, and
other lifestyle factors have all been proposed as possible
contributors to sex differences in NAFLD [10–13], the mo-
lecular mechanisms are unclear. Revealing the underlying
biological mechanisms driving the sex differences in
NAFLD can enable the identification of novel therapies and
preventive strategies to ameliorate the heightening global
health threat from NAFLD in a sex-specific and personal-
ized manner.
Recently, human genome-wide association studies
(GWAS) have revealed a handful of candidate causal
genes such as PNPLA3, SAMM50, PARVB, GCKR,
LCP1, LYPLAL1, PPP1R3B, TM6SF2, and TRIB1 for
NAFLD [14–16]. However, sex differences in genetic risks
have not been investigated in these studies. In addition,
NAFLD is strongly influenced by environmental factors
such as diet, which are difficult to control in human stud-
ies. Rodent models, on the other hand, allow for control
of environmental factors and collection of molecular traits
from the relevant tissues when examining a complex dis-
ease. To enable the study of sex-specific mechanisms of
NAFLD, hepatic steatosis and its relevant clinical and mo-
lecular traits were recently examined in both male and fe-
male mice of more than 100 distinct inbred and
recombinant inbred strains from the hybrid mouse diver-
sity panel (HMDP) [17]. These mice were treated with a
high fat and high sucrose diet to generate hepatic trigly-
ceride accumulation or steatosis, a hallmark of NAFLD. A
comprehensive NAFLD-associated and sex-specific multi-
omics data resource has also been generated, encompass-
ing genotyping of common genetic variants, transcriptome
data from liver and adipose tissue, and tissue-specific ex-
pression quantitative trait loci (eQTLs, reflecting the gen-
etic regulation of gene expression in individual tissues).
These data sets enable tissue-specific and sex-specific in-
vestigations of NAFLD mechanisms.
To fully leverage the multi-omic datasets from
HMDP mice and incorporate disease-associated mo-
lecular signals with strong, moderate, and subtle effects,
we have recently deployed an integrative approach to
identify potential causal pathways, gene networks, and
key regulators of NAFLD in males in a tissue-specific
fashion, followed by experimental validation of the
novel predictions [18]. In the current study, we apply
this validated approach to compare the NAFLD biology
between sexes to uncover the shared, male-specific, and
female-specific genes, processes, and networks poten-
tially driving NAFLD pathogenesis, thereby providing
more comprehensive tissue-specific insight into the dif-
ferential prevalence and manifestations of NAFLD be-
tween sexes.
Methods
Overall study design
We aimed to understand the sexually dimorphic mecha-
nisms underlying NAFLD using an integrative genomics
approach, Mergeomics [19, 20]. In our recent study [18],
we used this pipeline to integrate the multi-omics data
from the male mice of the hybrid mouse diversity panel
(HMDP) [17, 21] to identify causal NAFLD gene net-
works and predict key regulator (driver) genes in these
networks. Our subsequent in vivo and ex vivo experi-
ments supported the reliability of our multi-omics mod-
eling approach [18]. In our current study, we predicted
the NAFLD processes and their key driver genes using
the female HMDP mice [17, 21] and compared these
findings with those from the male-focused study [18]. As
illustrated in Fig. 1, we first reconstructed tissue-specific
coexpression networks and identified modules (groups
of co-expressed genes) using liver and adipose tissue
Fig. 1 Schematic representation of the methodology. Genotype,
liver and adipose tissue gene expression data, and hepatic
triglyceride phenotypic data from both sexes of the hybrid mouse
diversity panel (HMDP) mice were first integrated using Marker Set
Enrichment Analysis in the Mergeomics pipeline to predict sex- and
tissue-specific pathways perturbed in NAFLD. Then, potential
regulatory genes (key drivers) for male-specific, female-specific, and
shared pathways were identified using the Key Driver Analysis in
Mergeomics. TG triglyceride, eQTL expression quantitative trait loci,
GWAS genome-wide association studies
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gene expression data from female mice across more than
100 HMDP strains. Then, we integrated these modules
with GWAS of hepatic triglyceride levels together with
the eQTLs from liver and adipose tissue to identify gene
co-expression modules or biological pathways enriched
for NAFLD GWAS signals in females. The incorporation
of the genetic signals helped to infer causal modules and
pathways that are perturbed by genetic risks. Lastly, these
NAFLD-associated gene sets in females were mapped on
Bayesian networks that carry gene-gene regulatory infor-
mation to predict potential key driver genes of the
NAFLD processes. The findings from the female-specific
analysis were compared with those from the male-specific
study [18] to retrieve sex-specific and shared mechanisms.
HMDP study of NAFLD
The HMDP strains and the NAFLD study design with a
high-fat high-sucrose diet were previously described in
detail [17, 22]. Experimental procedures had been ap-
proved by the UCLA animal research committee. Female
mice from 103 mouse strains and male mice from 113
strains used in this study were purchased from the Jack-
son Laboratory and bred at University of California, Los
Angeles. These mice were fed an 8-week chow diet
followed by an 8-week high-fat high-sucrose diet with
16.8% kcal protein, 51.4% kcal carbohydrate, and 31.8%
kcal fat [17]. They were sacrificed after a 4-h fasting.
Hepatic lipid content measurement
Liver lipids were extracted from 365 female mice and 465
male mice by following an established method [23]. About
60 mg of liver was used for lipid extraction, and the dried
organic extract was dissolved in 1.8% (wt/vol) Triton
X-100 [17]. Colorimetric assay from Sigma (St. Louis,
MO) (triglyceride, total cholesterol, and unesterified chol-
esterol) and Wako (Richmond, VA) (phospholipids) were
used to determine the amount of liver lipids in each ex-
tract according to the manufacturer’s instructions.
RNA isolation and gene expression analyses of liver and
adipose tissues
Flash-frozen liver and epididymal adipose samples from
256 female mice from 103 strains and 288 male mice
from 113 mouse strains were weighed and homogenized,
as detailed in [17]. RNA was isolated using RNeasy col-
umns and global gene expression was profiled using
Affymetrix HT_MG430A arrays for 206 liver and 211
adipose tissues from females and 227 liver and 228 adi-
pose tissues from males (some mice had both liver and
adipose tissue samples analyzed, whereas others had
only one tissue passing quality control) [22]. ComBat
provided in the SVA tool [24] was used to remove batch
effects from the gene expression data.
Statistical analysis
Genome-wide association analysis of liver triglyceride and
tissue-specific eQTL analysis in females
Genotypes for 365 samples from 103 strains of female
mice were determined using the Mouse Diversity Array
[25]. SNPs with poor quality, a minor allele frequency of
< 5% or a missing genotype rate of > 10%, were removed
as previously described [17], resulting in about 200,000
SNPs. Genome-wide association mapping of the liver tri-
glyceride content and tissue-specific eQTLs were previ-
ously generated using Factored Spectrally Transformed
Linear Mixed Models [26, 27]. We used cis-eQTLs that
were defined within ±1 Mb region of the transcription
start and end sites of the genes. False discovery rate
(FDR) estimated by the q value approach [28] was used
for correcting for multiple testing. In the adipose tissue,
216,296 cis-eQTL associations were used (76,451 unique
cis-eSNPs and 1954 cis-genes), and in the liver, 241,463
cis-eQTL associations were used (81,076 unique cis-
eSNPs and 2168 cis-genes) at P < 1E−6 (FDR < 0.01).
Reconstruction of tissue-specific co-expression networks
from liver and adipose tissue transcriptome data from
females
Tissue-specific coexpression networks from gene expres-
sion data from 206 liver and 211 adipose tissue of female
mice in HMDP were constructed using two complemen-
tary network methods: Weighted Gene Co-expression
Network Analysis (WGCNA) [29] and Multiscale Embed-
ded Gene Co-expression Network Analysis (MEGENA)
[30]. WGCNA tends to cluster genes into large-sized
modules and assigns each gene into a single module,
whereas MEGENA defines smaller, more coherent mod-
ules and can assign each gene into multiple modules. As
shown in our recent study focusing on male NAFLD [18],
these two methods complement each other and can un-
cover hidden biology that could be missed by the other
method.
Both network methods assign the co-regulated genes
into the same coexpression module via hierarchical clus-
tering based on correlation of gene pairs. WGCNA is
based on agglomerative hierarchical clustering, whereas
MEGENA uses a divisive method of clustering. Gene
clusters are merged (in agglomerative) or split (in div-
isive) according to a distance measure. The distance
measure used in WGCNA is Topological Overlap Matrix
(TOM) subtracted from 1 (dissTOM= 1-TOM), which is
based on the edge weight (correlation score) between two
nodes (genes) by considering the edge weights of their
neighbors in the network. Distance between two clusters
is calculated as the average dissTOM score of all the gene
pairs (one gene from each cluster in a pair-wise manner).
Divisive clustering of MEGENA is based on the shortest
path distance measure and a nested k-medoids clustering
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that finds k optimal clusters at each step by minimizing
the shortest path distance within each cluster to define
more compact modules. The nested clustering process
continues until there is no more compact child cluster
found. MEGENA clusters genes in a multi-scale manner,
allowing the assignment of a gene into multiple modules,
but at different scales.
For each module from WGCNA or MEGENA, we an-
notated the putative biological functions using known
biological pathways curated from MSigDB database [31],
which incorporates KEGG, Reactome, and Biocarta path-
ways, using the one-tailed Fisher’s exact test. Bonferroni
correction was used to correct the P values. Pathways that
have an adjusted P < 0.05 and shared ≥ 5 genes with a
given module were deemed significant. Up to top five sig-
nificant pathways were used to annotate each module. For
modules without significant annotation terms, we used a
less stringent cutoff at uncorrected P < 5E−3 and ≥ 5
shared genes to annotate them with suggestive pathways
(indicated with an asterisk sign in figures and tables).
Module preservation analysis of the sex- and tissue-specific
coexpression modules
We evaluated the preservation of the female-specific coex-
pression modules within the male-specific modules and
vice versa, in a tissue-specific manner, using the module-
Preservation procedure from the WGCNA R package.
This procedure reports a Z-summary score to determine
whether a module is preserved in another data set by
using both connectivity and density statistics of the nodes
within a module. A Z-summary score > 2 means that there
is evidence for the preservation of a module in the second
condition/dataset tested [29]. The modulePreservation
procedure was applied in a tissue-matched manner be-
tween sexes to analyze the reciprocal preservation of the
modules obtained from the female mice expression data
with those from the male mice.
Filtering the coexpression modules based on their
correlation with NAFLD
For downstream analysis, we only kept the coexpression
modules that are relevant to the phenotype of interest
(liver triglyceride levels), based on Pearson correlation
between liver triglyceride and eigen genes of MEGENA
and WGCNA modules. To select NAFLD-correlated
modules, correlation P < 1E−3 was chosen as a cutoff,
which corresponds to a false positive rate of 0.1 based
on a permutation test. We generated 1000 random gene
sets, with a member size ranging from 20 to 500 genes,
as our negative controls, followed by calculating the
Pearson correlation between the trait and the eigen gene
of each negative control gene set. Among the 1000 nega-
tive controls, 102 gene sets had a correlation P < 1E−3
with the trait, representing false positives. The remaining
negative control gene sets were true negatives. There-
fore, at P < 1E−3, false positive rate = false positives/(false
positives + true negatives) = 0.1.
Mergeomics pipeline for multi-omics integration
Similar to our previous study on male NAFLD [18], in the
current study, we integrated the genetic (liver triglyceride
GWAS) and functional genomics data (eQTLs, coexpres-
sion modules, and pathways) from female HMDP to de-
fine pathways and coexpression networks that are
genetically associated with NAFLD using the Marker Set
Enrichment Analysis (MSEA) in Mergeomics [19, 20].
MSEA maps the genes within each pathway (from Bio-
carta, KEGG, and Reactome) or coexpression modules
(from MEGENA and WGCNA) to the expression single
nucleotide polymorphisms (eSNPs) through eQTLs of the
corresponding tissue in female mice. The cis-eQTLs
(within ±1 Mb of the transcription start and end sites) at
P < 1E−6 were used for mapping and eSNPs in linkage
disequilibrium were trimmed to keep only one eSNP per
linkage disequilibrium block based on the block informa-
tion reported by the PLINK2 tool [32]. The mapped
eSNPs for each module or pathway were queried for the
corresponding association P values from the hepatic tri-
glyceride GWAS. Then, a modified chi-square statistics,
which summarizes enrichment assessment across a range
of quantile-based cutoffs for the GWAS, is applied to each
eSNP set to assess the significance of enrichment for
stronger disease-associated GWAS P values by comparing
the GWAS P values of the given eSNP set against the
eSNPs of randomly generated gene sets [19]. Since this ap-
proach is not based on a single GWAS P value cutoff but
uses a set of quantile-based cutoffs, it produces more
stable enrichment scores and avoids artifacts. This modi-
fied chi-square statistics is defined as χ ¼Pni¼1 Oi−EiffiffiffiEip þκ ,
where O and E are the observed and estimated number of
positive findings (i.e., findings above the i-th quantile
point), respectively; n is the number of quantile points (10
quantile points were used ranging between the top 50%
and top 99.9% signals based on the rank of the GWAS P
values), and κ = 1 denotes a stability parameter that re-
duces the artifacts for small eSNP sets with low expected
counts. Benjamini-Hochberg approach was used to cor-
rect for multiple hypothesis testing and an FDR < 0.05
cut-off was used to define the significantly enriched gene
sets for a given GWAS.
If the significant gene sets (pathways or modules) for
NAFLD at FDR < 5% had significant sharing of member
genes, defined as gene overlapping ratio > 0.33 and Bon-
ferroni corrected Fisher’s exact test P value< 0.05, we
merged the overlapping gene sets into non-overlapping
“supersets” to reduce the redundancy. Occasionally, we
observed that a canonical pathway and a coexpression
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module, or two independent coexpression modules,
which were annotated with the same biological term but
did not share significant numbers of genes. In such
cases, they were kept as independent supersets despite
being annotated with the same (or similar) terms.
To predict potential key regulators, termed key drivers,
within the NAFLD supersets, the Weighted Key Driver
Analysis (wKDA) from Mergeomics pipeline was used.
wKDA projects the tissue-specific NAFLD-associated gene
sets onto a tissue-specific Bayesian network, which depicts
putatively causal relationships between genes, to identify
network hub genes (i.e., key driver genes), whose network
neighborhoods are significantly enriched for genes in the
NAFLD-associated supersets compared to the neighbor-
hood of a random gene in the network. This analysis has
been previously shown to successfully derive meaningful
biological findings [19, 33, 34]. Here, we mapped the hep-
atic triglyceride-associated supersets onto previously de-
fined liver and adipose tissue Bayesian networks, which
were curated from multiple human and rodent expression
datasets of previous studies [35–41] and constructed using
RIMBANET [42, 43] based on the gene expression pat-
terns, genetic information, causal inference, and previously
known regulatory relationships among the genes [18]. Since
the Bayesian networks incorporate genetic data, they can
reveal causal regulatory relationships between gene pairs
and enable the identification of potential regulators of dis-
ease genes and pathways. While combining the Bayesian
networks from these individual studies and defining a
union network for each tissue, we did not consider the edge
weights and the directions since some of the edge direc-
tions included in these Bayesian networks might be con-
flicting while the edges included in each individual network
were considered robust. Gene symbols given in the network
figures are illustrated in human orthologs since the curated
networks were taken from both human and rodent studies.
Key drivers of a NAFLD superset were identified based on
a modified chi-square statistics, as described for the MSEA
above, that evaluates the enrichment of the member genes
in the superset within the candidate key driver’s neighbor-
hood in the Bayesian network compared to that of a ran-
dom gene chosen from the same network. Benjamini-
Hochberg FDR was calculated, and genes with an FDR <
0.05 were determined as significant key drivers of a given
NAFLD superset. We identified the top key drivers in each
shared and sex-specific NAFLD-superset based on their
wKDA-FDR scores. Then, we extracted the subnetworks of
the top key drivers in each Bayesian network by gathering
the network neighbors of these key drivers.
Assessing overlap between the sex-specific NAFLD networks
and sex-hormone target genes
To explore the origin of the sex-specific NAFLD net-
works, we investigated whether the female networks are
enriched for estrogen target genes and whether the male
networks are enriched for androgen target genes. Liver
and adipose transcription factor regulatory networks were
obtained from the Functional Annotation of the Mamma-
lian genome (FANTOM) repository [44]. Tissue-specific
downstream genes of estrogen receptors and androgen re-
ceptors were extracted from the FANTOM networks and
used to assess overlaps with the female and male NAFLD
networks using Fisher’s exact test in a sex and tissue
matched manner (e.g., female liver NAFLD network genes
were overlapped with estrogen receptor target genes in
the FANTOM liver network).
Curation of previously studied NAFLD-relevant genes
As described in [18], 107 previously validated NAFLD-as-
sociated genes were taken from the DisGeNET database
[45], which manually curates the gene-disease associations
via text mining or from databases such as UniProt, Clin-
Var, Comparative Toxicogenomics Database (CTD), and
the GWAS Catalog. We compared these genes to the ones
identified by the current study as an in silico validation of
our findings.
Gonadectomy and ovariectomy
The gonadectomy and ovariectomy experiments were
performed as detailed previously [21, 46]. Male and fe-
male C57BL/6 J mice were purchased from The Jackson
Laboratory (Bar Harbor). Mice were maintained on a
chow diet (Ralston Purina Company) till 8 weeks of age
and then placed on a high-fat high-sucrose diet (Re-
search Diets D12266B) until 16 weeks of age. At 6 weeks
of age, the mice were gonadectomized under isoflurane
anesthesia (n = 4/group). Scrotal regions of male mice
were bilaterally incised, testes removed, and the incisions
closed with wound clips. Ovaries of female mice were re-
moved through an incision just below the rib cage. The
muscle layer was sutured, and the incision closed with
wound clips. In sham-operated control mice, incisions
were made and closed as described above. The gonads
were briefly manipulated but remained intact.
RNA library preparation and sequencing for liver and
adipose tissues from gonadectomized or ovariectomized
mice
Upon sacrifice, liver and gonadal adipose tissues were in-
stantly frozen in liquid nitrogen. Frozen tissues were ho-
mogenized in Qiazol, and following chloroform phase
separation RNA was prepared from the pink phase using
Qiagen miRNAeasy kits as per original protocol. BioA-
NAlyzer was used to validate total RNA quality (all sam-
ples had RIN > 8). RNA libraries were prepared by the
sequencing facility at the UCLA Neurosciences Genom-
ics Core using Illumina TruSeq Stranded kits v2,
followed by paired-end sequencing. Reads were aligned
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using STAR 2.5.2b, mm10 genome, and GENCOD M11
transcript annotation. Reads-per-gene tables were gener-
ated as part of STAR output, and DESeq2 was used for
differential expression analysis (see below).
Differentially expressed gene analysis between
gonadectomized/ovariectomized mice and sham-operated
mice
DESeq2 R Bioconductor package [47] was used to iden-
tify the genes that were differentially expressed between
the gonadectomized or ovariectomized mice and sham-
operated mice. DESeq2 tool estimates the variance-mean
dependence of the raw gene counts using a negative bino-
mial distribution and identifies the differentially expressed
genes between two groups (i.e., calculates the log2 fold
changes and corresponding P values for each gene) based
on a generalized linear modeling. Benjamini-Hochberg ad-
justed P < 0.05 was used to identify the differentially
expressed genes. Then, we analyzed enrichment of the dif-
ferentially expressed genes for the sex-specific NAFLD
subnetworks in the liver and adipose tissues using Fisher’s
exact test.
Results
Tissue-specific coexpression networks in females
To retrieve functional gene-gene relationships, gene
coexpression networks were constructed based on tran-
scriptome data of 206 liver and 211 adipose tissue sam-
ples of female mice from 103 HMDP strains using
WGCNA [29] and MEGENA [30] (see the “Methods”
section). For females, we identified 30 coexpression
modules in the liver and 30 modules in adipose tissue
using WGCNA, whereas with MEGENA, we identified
213 and 85 modules in the liver and adipose tissue, re-
spectively. These findings are comparable with those
from male mice [18]. Comparison of the modules be-
tween females and males revealed high preservation,
with ~ 95% and ~ 90% of the modules reciprocally pre-
served between sexes in the liver and adipose tissues, re-
spectively (Additional file 1). However, it is possible that
different modules may be perturbed in NAFLD in each
sex by different genetic risk factors.
Identifying modules that are correlated with NAFLD
phenotypes in females
Coexpression modules that are associated with the
NAFLD phenotype were identified based on the correl-
ation between the expression patterns of the module
eigengenes and hepatic triglyceride levels across all fe-
male samples (see the “Methods” section). We found 65
MEGENA modules (29 from liver and 36 from adipose)
and 10 WGCNA modules (7 from liver and 3 from
adipose) to be significantly correlated with hepatic tri-
glycerides. In the male HMDP data, we found similar
percentages of adipose modules to be associated with
NAFLD [18], but a higher percentage of NAFLD-associ-
ated liver modules (32% vs 13% for MEGENA modules
and 35% vs 23% for WGCNA modules in males vs fe-
males). These percentages suggest less prominent
NAFLD-related liver gene network perturbations in fe-
males compared to males, agreeing with the milder mea-
sures of liver injury in NAFLD females [11]. Functional
annotation of the NAFLD-associated modules in females
revealed diverse pathways ranging from various metabolic
pathways, immune pathways, to extracellular matrix
organization (Additional file 2). These NAFLD-correlated
modules were further integrated with GWAS signals from
female HMDP to identify potential causal mechanisms, as
detailed below.
Biological pathways and coexpression modules that
exhibit genetic association with NAFLD
To identify potential causal processes for NAFLD in fe-
male mice, genetic information (GWAS; which carries po-
tential causal inference), tissue-specific eQTLs, NAFLD-
correlated co-expression modules, and biochemical and
signaling pathways were integrated to infer groups of
functionally connected genes that together demonstrate
significant genetic association with NAFLD in females.
Out of the 1823 canonical pathways and the 75 hepatic
triglyceride-correlated female modules (36 from liver and
39 from adipose tissue), NAFLD GWAS signals from fe-
males were significantly enriched in 18 pathways and 5
liver co-expression modules informed by liver eQTLs, and
12 pathways and 6 adipose modules informed by adipose
eQTLs, at FDR < 5% (Additional file 3). Some of the sig-
nificant modules or pathways share member genes and
represent similar biological processes. To reduce the re-
dundancy, we derived “supersets” by merging overlapping
gene sets; thereby each superset was comprised of one or
more overlapping NAFLD-associated gene sets (see the
“Methods” section). These supersets still carry enrichment
for strong NAFLD genetic signals that their constituents
carried (Additional file 4). Some of the gene sets were an-
notated with the same term but were not merged because
the overlap in gene members was not sufficient to meet
our criteria as specified in the “Methods” section (e.g., in
female adipose tissue, 2 modules were annotated with
extracellular matrix and matrisome terms but were not
merged). Comparison of supersets between tissues revealed
6 liver-specific supersets (e.g., innate immune system, oxi-
dative phosphorylation, metabolism of vitamins and cofac-
tors), 6 adipose-specific supersets (e.g., branched-chain
amino acid metabolism, extracellular matrix glycoproteins,
axon guidance), and 8 cross-tissue supersets (e.g., apop-
tosis/cell cycle, gene expression regulation, growth factor
receptor signaling) (Fig. 2).
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Comparison of the NAFLD-associated supersets between
female and male mice
Comparison of the female NAFLD supersets with those
from the males [18] revealed five supersets (lipid metab-
olism, apoptosis/cell cycle, signal transduction, and tran-
scription pathways) to be shared across tissues for both
sexes (Fig. 3a; Additional file 4). In liver, oxidative phos-
phorylation and transmembrane transport of small mol-
ecules were shared between sexes, whereas branched-
chain amino acid metabolism was shared between sexes
in the adipose tissue (Fig. 3a).
Besides the consistent pathways between tissues and
sexes discussed above, we also found that certain path-
ways demonstrate differential tissue-specificity between
males and females (Fig. 3a; Additional file 4); innate im-
munity was specific to liver in females but was specific
to adipose tissue in males, whereas the adaptive immune
system and B cell receptor (BCR) signaling superset was
shared by both tissues in males but was adipose-specific
in females. Therefore, the two arms of the immune sys-
tem appear to act in different tissues during NAFLD in
females, whereas both the innate and adaptive immune
systems were found to be perturbed in adipose tissue in
males. Although the adaptive immune system is impli-
cated in both female and male adipose tissue, it still has
a sex-specific pattern since males have transforming
growth factor-beta (TGFβ) and BCR signaling pathways,
while females have a T cell receptor (TCR) pathway.
TGFβ is a cytokine that can induce profibrogenic gene
expression and may promote the progression from stea-
tosis to steatohepatitis in males [48]. Additionally, males
showed perturbations in fatty acid, triacylglycerol, and
ketone body metabolism in both tissues, but this path-
way was liver-specific in females. On the other hand,
growth factor receptor signaling and cancer pathways
were adipose-specific in males but identified in both tis-
sues in females.
Processes that were specific to one sex were also iden-
tified. For instance, insulin signaling-related terms were
observed only in the adipose tissue of male mice. In
addition, more metabolism-related pathways (e.g., lipid,
lysophospholipid, fatty acid) were identified in males com-
pared to their female counterparts. Another male-specific
adipose pathway was Wnt signaling, which has diverse ef-
fects on cellular metabolism and inflammation. Perturbed
Wnt signaling is known to contribute to increased inflam-
mation and decreased adipogenesis, leading to triglyceride
accumulation and acceleration of NAFLD. Wnt signaling
is known to crosstalk with Notch and TGFβ signaling,
which were also found to be perturbed only in male liver
and adipose tissues, respectively. Peroxisome, cytochrome
p450 drug metabolism, and G2-M DNA damage check-
point are additional male-specific pathways in the liver
(Additional file 4). These findings may help explain the
more severe metabolic syndrome and liver injury, as well
as the higher ratio of DNA damage and inflammation
markers observed in males.
For females, metabolism of vitamins and cofactors and
ion channel transport were uniquely identified in liver
(Fig. 3b), whereas extracellular matrix glycoproteins,
axon guidance, and TCR signaling were female-specific
in adipose tissue. Ion transport has been associated with
oxidative stress and plays an important role in the pro-
gression of liver steatosis to insulin insensitivity and
more severe conditions such as hepatocellular carcinoma
[46, 49–52]. Regarding the vitamins and cofactors path-
way, adverse impacts of vitamin A, B12, D, and E defi-
ciency in NAFLD, fibrosis, and NASH have been studied
[53–57]. Vitamin A and D are involved in extracellular
matrix remodeling during liver fibrosis, B12 deficiency
impairs fatty acid oxidation [54], and vitamin E reduces
endoplasmic reticulum stress and prevents liver inflam-
mation and apoptosis. Some of these terms have been
associated with NAFLD before, but here, we provide
novel evidence that they may play a causal role in
NAFLD based on the fact that we incorporated genetic
signals in our analysis.
Predicting key driver genes of the NAFLD-associated
gene supersets in females
To predict the potential regulators of the NAFLD genes
and pathways, we used liver and adipose tissue-specific
Bayesian networks [42, 43] that involve causal or regula-
tory relationships between gene pairs and were independ-
ently constructed from previous human and mouse
studies [35–41]. Numerous key drivers were predicted for
each of the female NAFLD-associated superset at FDR <
5% (top key drivers for each superset in Additional file 4;
full list in Additional file 5). We found that 23 of all
significant key drivers were among the 107 previously
reported NAFLD genes curated in DisGeNET
Fig. 2 Comparison between NAFLD processes perturbed in the liver
and adipose tissue for females. Putative causal pathways that are
common to both tissues and unique to each tissue are listed. Co-
expression modules are annotated with the most over-represented
gene ontology terms. “NA” indicates no over-represented terms
were found for a given module. BCAA branched-chain amino acid,
BCR B cell receptor, ECM extracellular matrix, TCR T cell receptor
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(Additional file 6), including AHSG, FASN, RBP4, and
SREBF1, which were found to be key drivers in both liver
and adipose tissue in our analysis.
We compared the top key drivers predicted for the fe-
male NAFLD subnetworks with those predicted for
males in a tissue-specific manner. As elucidated in Fig. 4
and detailed in Additional file 4, the shared liver or adi-
pose key drivers between sexes included genes with di-
verse functions involved in fatty acid and cholesterol
metabolism (such as ACOT2, DECR1, DHCR7, SQLE,
INSIG1, and ACSS2), branched-chain amino acid catab-
olism (such as BCKDHA, MCCC1, and ECHS1), cell
cycle (such as CDCA8, MKI67, and CCNA2), extracellu-
lar matrix (such as FBN1, COL1A2, and CCDC80), and
immune system and inflammation (such as RELB, IFNG,
and CXCL10). The key drivers and the pathways they
regulate intimately interconnect in gene networks (Fig. 4a
for liver and Fig. 4b for adipose tissue).
We also identified key drivers (Additional file 4) and
their associated subnetworks (Fig. 4c–f ) for the
sex-specific mechanisms in a tissue-specific manner.
Many top female-specific key drivers are immune-related
genes such as PTPRO, SH3BP2,TYROBP, and C8B (Fig. 4c
for liver, Fig. 4d for adipose). In contrast, male-specific key
drivers show broader functional diversity including
various aspects of metabolism (e.g., fatty acids—FASN and
CD36, mitochondria—CPT2 and CHCHD6), insulin sig-
naling (e.g., FASN, GYS1), immune system (e.g., INPP5D,
FCER1G, NCKAP1L), and cell growth and apoptosis
(ANXA2, CIDEC) (Fig. 4e for liver, Fig. 4f for adipose).
Notably, both the shared and sex-specific key driver sub-
networks contain numerous known human GWAS genes
such as PNPLA3 and TRIB1, but the GWAS genes are less
likely to be key drivers. The combined subnetworks of
NAFLD processes that are female-specific or shared be-
tween sexes are given in Additional file 7 A and B for liver
and adipose tissue, respectively, whereas the male-specific
or shared networks were previously presented in [18].
Potential regulation of the NAFLD networks by sex
hormones
To explore the potential role of sex hormones in regulat-
ing the sexually dimorphic NAFLD genes and pathways
identified, we tested the sex-specific liver and adipose tis-
sue key driver subnetworks for enrichment of known tar-
get genes of estrogen receptors (ESR1, ESRRA, ESRRB,
and ESRRG) and androgen receptor (AR) based on FAN-
TOM5 transcription factor regulatory networks [44] from
matching tissues. We found that female-specific liver and
adipose NAFLD networks were strongly enriched with
Fig. 3 Comparison between NAFLD processes perturbed in the liver and adipose tissue of both sexes. Putative causal pathways that are a shared
between sexes in one or both tissues and b unique to each sex and each tissue are listed. TCA the citric acid
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target genes of estrogen receptors and male-specific key
driver subnetworks showed a strong enrichment for the
target genes of AR in both tissues (Additional file 8). We
also investigated whether individual key drivers in the
sex-specific networks are targets of sex hormones or show
interactions with sex hormones. Among the female-specific
key drivers, NCKAP1L is a target of estrogen receptor
ESRRA; C8B is a target of multiple estrogen receptors
ESRRA, ESRRB, and ESRRG; and SH3BP2 is a target of
ESR1 [44]. Among the male-specific key drivers, CHCHD6
is a target gene of the androgen receptor. These results sug-
gest that sex hormones may regulate the sex-specific key
drivers and pathways and partially explain the sexual di-
morphism in NAFLD.
Gonadectomy and ovariectomy experiments support the
regulatory roles of sex hormones in NAFLD sexual
dimorphism
To more directly test the role of sex hormones, we com-
pared our NAFLD subnetworks with the transcriptome
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Fig. 4 Bayesian gene network representations of NAFLD pathways and their key driver genes. a Liver Bayesian subnetwork comprised of shared
liver NAFLD supersets between sexes and their top key drivers. b Adipose tissue Bayesian subnetwork comprised of shared adipose NAFLD
supersets between sexes and their top key drivers. Female-specific c liver Bayesian subnetworks and d adipose tissue Bayesian subnetworks and
their corresponding top key drivers. Male-specific e liver Bayesian subnetworks and f adipose tissue Bayesian subnetworks and their
corresponding top key drivers. Key driver genes are shown with larger node sizes, human GWAS candidate genes are represented in hexagon
shapes, and the rest of the genes are represented by smaller node sizes. Each NAFLD-associated superset is indicated with a distinct color in each
network. Network genes that are not members of the NAFLD supersets are represented in gray. See also Additional file 4
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of both liver and adipose tissues from gonadectomized
and ovariectomized mice. At FDR < 5%, we identified
2435 and 196 differentially expressed genes in liver tis-
sue of males and females, respectively, and 1804 and
1491 differentially expressed genes in adipose tissue of
males and females, respectively (Table 1). These results
suggest a significant impact of testosterone on both male
tissues and estrogen on the female adipose tissue. In
contrast, female liver tissue was less affected by estrogen
deficiency. We analyzed the enrichment of each differen-
tially expressed gene list in our sex-specific NAFLD sub-
networks (Fig. 4c–f ) for the corresponding sex and
tissue. Consistent with the numbers of differentially
expressed genes from the gonadectomy/ovariectomy ex-
periments, the female liver NAFLD subnetworks (Fig. 4c)
had the smallest number of genes (86 compared to hun-
dreds in the other networks). Only two genes in this
subnetwork were found to be affected by estrogen defi-
ciency in the female liver. In stark contrast, about half of
the male liver NAFLD subnetwork genes (100 of 218
genes) were found to be affected by testosterone defi-
ciency in male liver tissue. Similarly, significant overlaps
between the adipose NAFLD subnetwork genes and the
adipose genes affected by sex hormone deficiency were
observed for both sexes. Besides, some of our top key
driver genes were among the differentially expressed
genes for the corresponding tissue and sex as listed in
Table 1 (see also Fig. 4c–f ). These results support that
sex hormones are involved in the regulation of the
male-specific NAFLD processes in both tissues but only
adipose pathways in females.
Discussion
To understand the sexual dimorphism observed in
NAFLD, here, we compared the genetically perturbed
mechanisms in NAFLD between sexes via integration of
multi-omics data including GWAS, tissue-specific tran-
scriptomic and eQTL data, and NAFLD phenotypic data
from > 100 inbred and recombinant inbred mouse strains
for females and males. This comprehensive data-driven
analysis revealed both shared and sex-specific pathways,
regulatory genes, and networks, thereby providing
molecular insights into the sex differences in NAFLD.
Furthermore, both our in silico FANTOM5 transcription
factor analysis and in vivo hormone modulation experi-
ments support a strong role of sex hormones in the regu-
lation of sex-specific NAFLD pathways.
We conducted our analysis in a tissue and sex-specific
manner, identifying and comparing causal NAFLD pro-
cesses between sexes in the liver and adipose tissue since
those are the most relevant and implicated tissues in
NAFLD pathogenesis [48]. We observed numerous pro-
cesses that are shared by both sexes, such as the cell
cycle, apoptosis, and lipid metabolism in both tissues,
fatty acid metabolism, oxidative phosphorylation, and
growth factor receptor signaling in liver tissue, and
branched-chain amino acid metabolism, adaptive im-
mune system, and post-translational protein modifica-
tion in adipose tissue (Additional file 4). Many of these
pathways have been previously associated with NAFLD
[48, 58, 59], confirming the reliability of our approach.
The consistency of these shared terms between sexes
highlights them as the core processes that can be tar-
geted generally for NAFLD.
To facilitate the identification of potential targets for
the above-shared pathways, we used a network modeling
approach to define candidate regulator genes or key
drivers. The predicted key drivers were found to orches-
trate genes in the NAFLD processes shared by both
sexes, forming highly connected subnetworks containing
numerous previously known NAFLD genes (such as
AHSG, FDFT1, FASN, ACADVL, PNPLA3, GCKR,
LYPLAL1, and LCP1) (Fig. 4a, b). In liver tissue, many
key drivers are involved in fatty acid and cholesterol me-
tabolism, such as ACOT2 and DHCR7. In adipose tissue,
notable key drivers such as BCKDHA, MCCC1, and
ECHS1 are key enzymes involved in branched-chain
amino acid catabolism. Branched-chain amino acids are
known to be involved in numerous physiological activ-
ities related to nutrition, metabolism, and immune sys-
tem processes and metabolic disorders such as insulin
resistance and NAFLD. Impairments in branched-chain
amino acid degradation deteriorate the TCA cycle, which
may lead to mitochondrial dysfunction in NAFLD [60].
Table 1 Overlap between sex-specific NAFLD subnetworks and DEGs affected by sex hormones
Tissue Sex Network size DEG size Overlap gene size
(overlap KD size)
Overlap KD list Fold change P value
Liver M 218 2435 100 (14) C8B, CYP7B1, SLC16A7, SLC16A5, CD36,
MGST3, NCKAP1L, INPP5D, ANXA2, HCK,
FCER1G, FGL2, CIDEC, TBC1D15
6.13 8.28E−71
F 86 196 2 (0) – 3.86 8.68E−02
Adipose M 261 1804 71 (8) FASN, AACS, ETFDH, GYS1, ECHS1,
SH3D21, SLC2A3, PMEPA1
4.39 9.34E−35
F 206 1491 34 (5) MSLN, GPM6A, PTGIS, RSPO1, BNC1 3.22 4.57E−13
One-sided Fisher’s exact test was used to calculate enrichment P values
Kurt et al. Biology of Sex Differences            (2018) 9:46 Page 10 of 14
Identification of the key drivers that regulate the shared
pathogenic processes between sexes may facilitate the
prioritization of targets to treat the disease in the general
population.
In addition to the shared pathways, we observed
female-specific processes in the liver and adipose tissue
(Additional file 4) and predicted their potential regula-
tors. NCK-associated protein 1-like (NCKAP1L) and
TYRO protein tyrosine kinase binding protein (TYR-
OBP) were found to be the top key drivers of the innate
immune system in the liver. The same key drivers have
been previously found to regulate an inflammation net-
work involved in a large number of diseases including
diabetes, obesity, cardiovascular disease, and cancers
[61]. Another top key driver regulating a female-specific
process in the liver is complement C8 beta chain (C8B)
in the complement pathway. It has not been previously
associated with NAFLD; however, it is connected to
three human NAFLD GWAS genes (GCKR, LYPLAL1,
and TM6SF2) in our liver network, making it a strong
novel candidate target for NAFLD. SH3 domain-binding
protein 2 (SH3BP2), is a female-specific adipose key
driver for the TCR signaling and lysosome module.
SH3BP2 has not been previously associated with NAFLD
to the best of our knowledge, but it is a target of estro-
gen receptor 1 according to FANTOM5 adipose tissue
gene regulatory network [44], which may support our
sex and tissue-specific finding on SH3BP2.
Notably, lipid-related processes (e.g., phospholipid, lyso-
phospholipid) are prominent in males (Additional file 4)
[18] but not in females. Another male-specific process,
Notch signaling, was previously found to be correlated
with insulin resistance, hepatic steatosis, alanine amino-
transferase, and NAFLD activity score in liver biopsies
[62]. Our results support a causal role of this pathway in
NAFLD development, particularly in males. We also ob-
served male-specific adipose tissue pathways such as Wnt
and insulin signaling, which agrees with the observations
that insulin resistance is strongly correlated with NAFLD
mainly in males and that males with NAFLD have higher
glucose and lower adiponectin levels than females [11].
Differences in insulin sensitivity may partially explain sex
differences in NAFLD. Male-specific top key drivers in-
clude CHCHD6 and CD36 in liver and FASN and CPT2 in
adipose tissue, which primarily regulate mitochondrial
function and fatty acid metabolism. Coiled-coil-helix-coi-
led-coil-helix domain containing 6 (CHCHD6) was experi-
mentally validated in our recent study as a novel key
regulator of NAFLD by impairing mitochondrial functions
in the liver [18]. These male-specific pathways and regula-
tors along with the female-specific ones discussed earlier
can facilitate future efforts to investigate the sex-specific
mechanisms in NAFLD and may serve as potential thera-
peutic targets for sex-dependent treatments.
It is noted that estrogen deficiency in mice fed a
high-fat diet leads to accelerated NAFLD progression
[13], and after menopause, the rate and severity of
NAFLD increases in females [10, 12]. Testosterone has
also been associated with a protective role in NAFLD in
males [46, 63, 64]. Since both male and female sex hor-
mones might have a role in slowing the NAFLD progres-
sion, we also investigated the potential effects of the sex
hormones on the sexual dimorphism in NAFLD using
both an in silico transcription factor analysis and in vivo
gonadectomy/ovariectomy experiments. Both analyses
support significant overlaps between the sex-specific
liver and adipose tissue NAFLD networks and sex hor-
mone target genes. The significant overlaps also include
our top key driver genes for the corresponding tissue
and sex (Table 1, Fig. 4c–f ). These results support a role
of sex hormones in the regulation of the sex-specific
NAFLD networks and pathways. However, hormones
only partially explain the sex-specific networks. In the
case of females, ovariectomy had limited effects on liver
gene expression, suggesting minor contribution of estro-
gen deficiency to the female-specific liver networks.
Since the ovariectomy experiment was carried out in
adulthood, it is possible that developmental estrogen ex-
posure plays a stronger role in shaping female liver net-
work. It is also plausible that sex chromosomes play an
important role, particularly in the female liver. Further
investigations are required to explore the role of sex
chromosomes in regulating sexually dimorphic networks
for NAFLD.
A major strength and novelty of our study is the
utilization of a multi-omics integrative approach to iden-
tify genetically causal or perturbed sex- and tissue-specific
processes and key regulatory genes in NAFLD based on
genetics, functional genomics, and gene regulatory net-
works. The integration of multidimensional datasets en-
abled us to derive one of the most comprehensive views of
the genes and pathways that are likely perturbed by gen-
etic risks of NAFLD in both males and females, thereby
significantly enhancing our understanding of sexual di-
morphisms in NAFLD. Compared to a previous study ex-
ploring sex differences in the same animal cohort, which
focused on a few genome-wide significant loci and
pair-wise correlations between phenotypes and individual
genes [46], our study uniquely leveraged the full spectrum
of molecular associations across multi-omics dimensions
and benefited from network representations of regulatory
relationships. In addition to confirming mitochondrial
function, oxidative phosphorylation, and transmembrane
transport as important NAFLD processes [46], we identi-
fied numerous sex-specific genes and pathways that were
missed in the previous study.
A principle limitation of our study is that our analyt-
ical framework only considers the effect sizes but not
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the directionality of NAFLD GWAS associations and
gene expression changes. As such, it is difficult to infer
if the sex-specific pathways are protective or pathogenic
for NAFLD. For example, it is possible that some of the
sex-specific pathways reduce instead of promote disease
risks. Building on our recent successes in experimentally
validating predictions from the integrative genomics ap-
proach described here, future studies that perturb indi-
vidual sex-specific pathways and key drivers identified
here will help confirm the causality of the predicted
genes and pathways and determine whether they should
be activated or inhibited to ameliorate NAFLD.
Our sex-specific findings help understand the long-ob-
served sexual dimorphism in NAFLD and provide in-
sights into the potential differential pathogenic pathways
between males and females, which can guide future de-
velopment of sex-specific therapeutics in translational
studies. Although our study is carried out in mice, there
is strong evidence for replication of our findings in hu-
man studies. For instance, results from our previous
male-focused study [18] are consistent with an inde-
pendent human study demonstrating the functional as-
sociations of FASN, PKLR, and THRSP with NAFLD
[65]. Additionally, our NAFLD gene subnetworks (Fig. 4)
contained human NAFLD GWAS genes such as
PNPLA3, LCP1, and TMSF2. Furthermore, our recent
study examining liver fibrosis identified significant over-
laps in the genes and pathways between mouse and hu-
man [66]. These observations support the translatability
of our findings from mouse studies to human NAFLD or
NASH pathogenesis.
Conclusions
The National Institute of Health and the Food and
Drug Administration have prioritized personalized
medicine as a key to developing effective therapies
[67]. Sex is one of the important factors to consider
when developing personalized medicine as it can
affect drug dose level, adverse reactions, and re-
sponses. There are numerous reported sex differ-
ences in liver disease drugs with regard to the rate
of response and adverse reactions, but few of these
sex differences are understood [12]. Our multi-omics
integrative approach combining genetic, gene expres-
sion, functional genomics, and network modeling
delineated genes, pathways, and tissue-specific net-
works that contribute to the sexual dimorphism of
NAFLD. Our findings support the existence of core
pathogenic processes that can be targeted in both
sexes and pinpoint sex-specific mechanisms to guide
differential therapeutic options for males and females
to more effectively mitigate NAFLD in a personal-
ized manner.
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